A simple system for grading the response of breast cancer to neoadjuvant chemotherapy

Annals of Oncology

Volumn 21, Issue 3, 2009, Pages 481-487

  Rodenhuis, S ^a   Mandjes, I A M ^a   Wesseling, J ^a   van de Vijver, M J ^a   Peeters, M J T D F Vrancken ^a   Sonke, G S ^a   Linn, S C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Chemotherapy; Neoadjuvant; Response evaluation

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; ORGAN WEIGHT; PREOPERATIVE CARE; PRIORITY JOURNAL; SCORING SYSTEM; SENTINEL LYMPH NODE;

EID: 77949592485     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp348     Document Type: Article

References (20)

1. Mauri D, Pavlidis D, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
2. Gralow JR, Burstein HJ, Wood W et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26: 814-819.
3. Von Minckwitz G, Kümmel S, Vogel P et al. for the German Breast Group. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-551.
4. Esteva FJ, Hortobagyi GN. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? J Natl Cancer Inst 2008; 100: 521-523.
5. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
6. Sachelarie I, Grossbard ML, Chadha M et al. Primary systemic therapy of breast cancer. Oncologist 2006; 11: 574-589.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
8. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-4422.
9. Hannemann J, Oosterkamp HM, Bosch CA et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23: 3331-3342.
10. Loo CE, Teertstra HJ, Rodenhuis S et al. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. Am J Roentgenol 2008; 191: 1331-1338.
11. Hannemann J, Kristel P, Van Tinteren H et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006; 95: 1334-1341.
12. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
13. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
14. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
15. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
16. Straver ME, Glas AM, Hannemann J et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009. doi 10.1007/s10549-009-0333-1.
17. Bueno de Mesquita JM, Van Harten WH, Retel VP et al. Use of 7-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007; 8: 1079-1087.
18. Buzdar AU, Valero V, Ibrahim NK et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13: 1-3.
19. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH-trial. In San Antonio Breast Cancer Symposium, San Antonio, Texas, 2008 (Abstr 31).
20. Peintinger F, Buzdar AU, Kuerer HM et al. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 2008; 12: 2020-2025.